Cinclus Pharma

About linaprazan glurate
Linaprazan glurate has been developed by Cinclus Pharma and is a prodrug of the P-CAB linaprazan, the main and active metabolite, originally developed by AstraZeneca. Linaprazan and linaprazan glurate have been evaluated in more than 30 phase I and two phase II studies, exposing over 3,000 individuals to linaprazan or linaprazan glurate. Linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Linaprazan glurate has the potential to heal erosions in the esophageal mucosa caused by leaked stomach acid and to alleviate GERD symptoms more effectively and rapidly than current pharmaceutical treatments, including proton pump inhibitors (PPI). The favorable safety, efficacy, and pharmacokinetic properties of linaprazan glurate have been documented in several phase I and one phase II study. Planning for the initiation of the phase III program is underway, with an expected study start in 2025.

About GERD
Gastroesophageal reflux disease (GERD) is a digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the esophagus and the stomach, causing a backflow of stomach contents into the esophagus. This leads to erosions, acid reflux, and heartburn caused by stomach acid. Approximately 133 million adults in the US and EU-30 suffer from GERD. The global market for acid reflux is dominated by proton pump inhibitors (PPI). To heal the most vulnerable patients with the most severe erosions, acid control must be maintained around the clock. Overall, about 10 million patients in the EU and the US suffer from the most severe form of eGERD. Many of these are not helped by the current standard treatment, indicating a clear need for better medications to treat GERD. Linaprazan glurate is developed to meet these patients' needs.